Follow
Gustavo Aroca Martinez
Gustavo Aroca Martinez
Other namesAroca-Martinez Gustavo, Aroca.gustavo
Universidad Simón Bolívar, Barranquilla, Colombia.
Verified email at unisimon.edu.co
Title
Cited by
Cited by
Year
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
J Sadoff, G Gray, A Vandebosch, V Cárdenas, G Shukarev, B Grinsztejn, ...
The new england journal o f medicine 384, 2187-2201, 2021
24362021
Rivaroxaban with or without aspirin in stable cardiovascular disease
JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ...
New England Journal of Medicine 377 (14), 1319-1330, 2017
23522017
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
P López-Jaramillo, E Barbosa, DI Molina, R Sanchez, M Diaz, ...
The Lancet, 2019
22302019
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
New England Journal Medicine 383 (23), 2219-229, 2020
15212020
Cholesterol lowering in intermediate-risk persons without cardiovascular disease
S Yusuf, J Bosch, G Dagenais, J Zhu, D Xavier, L Liu, P Pais, ...
New England Journal of Medicine 374 (21), 2021-2031, 2016
10032016
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
C Anand,S,Bosch,J,Eikelboon,J
THE LANCET 391 (1017), 219-229, 2018
9252018
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
B Pitt, G Filippatos, R Agarwal, S Anker, G Bakris, P Rossing, A Joseph, ...
the New England Journal of Medicine 385 (4), 2252-2263, 2021
8102021
Blood-pressure lowering in intermediate-risk persons without cardiovascular disease
EM Lonn, J Bosch, P López-Jaramillo, J Zhu, L Liu, P Pais, R Diaz, ...
New England Journal of Medicine 374 (21), 2009-2020, 2016
7862016
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
The Lancet, 2019
5302019
Blood-pressure and cholesterol lowering in persons without cardiovascular disease
S Yusuf, E Lonn, P Pais, J Bosch, P Lopez-Jaramillo, J Zhu, D Xavier, ...
New England Journal of Medicine 374 (21), 2032-2043, 2016
4772016
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Gastroenterology, 2019
4012019
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
SJ Connolly, JW Eikelboom, J Bosch, G Dagenais, L Dyal, F Lanas, ...
LANCET 20 (391), 205-218, 2018
3982018
May Measurement Month 2017: an analysis of blood pressure screening results worldwide
THE LANCET GLOBAL HEALTH 6 (7), 736-743, 2018
3572018
May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension.
European heart journal, 2019
2532019
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
G Filippatos, Stefan D. Anker, R Agarwal, B Pitt, LM Ruilope, P Rossing, ...
CIRCULATION 143 (6), 540-552, 2021
2272021
May Measurement Month 2019 The Global Blood Pressure Screening Campaign of the International Society of Hypertension
T Beaney, A Schutte, G Stergiou, C Borghi, als. et
HYPERTENSION 76 (2), 333-341, 2020
2062020
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of …
H Gerstein, H Colhoun, G Dagenais, R Diaz, M Lakshmanan, P Pais, ...
Diabetes, Obesity and Metabolism 20 (1), 42-49, 2018
1962018
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, doubleblind, placebo-controlled trial
RA Furie, G Aroca, MD Cascino, JP Garg, BH Rovin, A Alvarez, ...
Annals of the Rheumatic Diseases 80 (1), 2021
1942021
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies
Canadian Journal of Cardiology 33 (8), 1027-1035, 2017
1932017
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
LM Ruilope, R Agarwal, SD Anker, GL Bakris, G Filippatos, C Nowack, ...
AMERICAN JOURNAL OF NEPHROLOGY 50, 345-356, 2019
1722019
The system can't perform the operation now. Try again later.
Articles 1–20